Workshop on rising Head & Neck cancer in Nepal

A workshop on the fight against rising head and neck cancers (HNC) in Nepal has been organized recently by leading oncologists from India and Nepal. It was conducted at Radisson Hotel in Kathmandu. The workshop was attended by top Oncologists from Fortis Memorial Research Institute, Gurugram, India : Dr A K Anand (Radiation Oncology), Dr Ankur Bahl (Medical Oncology), Dr Vedant Kabra (Surgical Oncologist ), Dr Ishita B Sen (Nuclear Medicine Physician) and Dr Neha Kakkar (Radiation Oncology) along with  Key Oncologists from Nepal: Dr Sudhip Shrestha (Medical Oncologist) and Dr Prabhat Thakur (ENT Surgical Oncologist).

The agenda of the conference was to discuss case studies and clinical issues related to head and neck cancer treatment along with best practices that can be adopted to ensure optimal clinical outcomes for the patients. The key topics discussed were – Treatment management in advanced head and neck cancers, Treatment management of recurrent/metastatic head and neck cancers, Treatment Options in recurrent head and neck cancers.

 “The trend of HNCs is increasing in Nepal especially oral cancers. Awareness about risk factors, effective and early screening programs and comprehensive treatment is the need of the hour to decrease the burden of HNCs. The past few years, with advanced technology and targeted chemotherapy, the success rate for treatment and patient’s survival has substantially improved, especially in the context of Head and Neck cancers”, said Dr A K Anand (Radiation Oncology), Fortis Memorial Research Institute, Gurugram.

Noteworthy, Fortis Memorial Research Institute is one of the leading comprehensive cancer care hospitals in India.  Fortis Healthcare Limited is one of India’s largest integrated and trusted multi-specialty chain of hospitals. It has been investing in building a robust cancer care infrastructure backed by the latest technological innovations, targeted precision medicine and highly skilled doctors.

By Business Correspondent

Leave a Reply